Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login